Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on history of skeletal complications

Clinical Lung Cancer

Volumn 6, Issue 3, 2004, Pages 170-174

  Hirsh, Vera ^a   Tchekmedyian, N Simon ^b   Rosen, Lee S ^c   Zheng, Ming ^d   Hei, Yong Jiang ^d  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b Pacific Shores Medical Group   (Canada)

^c Cancer Institute Medical Group   (Canada)

^d Novartis Pharmaceuticals Corporation   (Canada)

Author keywords

Bisphosphonate; Bone metastases; Non small cell lung cancer; Skeletal related event

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ANAMNESIS; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MORBIDITY; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SOLID TUMOR; SPINAL CORD COMPRESSION;

EID: 10244250263     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.030     Document Type: Article

References (15)

1. American Cancer Society. Cancer Facts & Figures 2004. Atlanta: ACS, 2004.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80(suppl):1588-1594.
3. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18.
4. Hansen BH, Keller J, Laitinen M, et al. The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl 2004; 75:11-15.
5. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small-cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. For the Zoledronic Acid Prostate Cancer Study group. Cancer 2004; 100: 2613-2621.
6. Delea TE, McKiernan JM, Liss M, et al. Impact of skeletal complications on total medical care costs in lung cancer patients with bone metastases. Proc Am Soc Clin Oncol 2004; 23:533 (Abstract #6064).
7. Lacerna L, Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol 2003; 30(suppl 16):150-160.
8. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157.
9. Major PP, Cook RJ, Chen BL, et al. Survival-adjusted multiple event analysis of skeletal complications from bone metastases: a comprehensive analysis of treatment benefit. Presented at: IVth International Conference on Cancer-Induced Bone Diseases; December 7-9, 2003; San Antonio, TX.
10. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10:1100-1120.
11. Hirsh V, Tchekmedyian NS, Rosen L, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on prior history of skeletal complications. Proc Am Soc Clin Oncol 2004; 23:669 (Abstract #7226).
12. Dedes KJ, Szucs TD, Bodis S, et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 2004; 22:435-444.
13. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 2004; 23:622 (Abstract #7022).
14. Shepherd FA, Dancy J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
15. MacDonald CD, Pickering LM, Mansi JL, et al. Anti-cancer effects of bisphosphonates in lung cancer cell lines. Proc Am Soc Clin Oncol 2004; 23:685 (Abstract #7289).